View in EDS HTML Full Text PDF Full Text

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.

Saved in:
Bibliographic Details
Title: Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
Authors: Qualls D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Noy A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Straus D; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Matasar M; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Moskowitz C; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Seshan V; Department of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Salles G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Younes A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Batlevi CL; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 738-741. Date of Electronic Publication: 2023 Jan 15.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36642966
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Qualls+D%22">Qualls D</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Noy+A%22">Noy A</searchLink>; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Straus+D%22">Straus D</searchLink>; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Matasar+M%22">Matasar M</searchLink>; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Moskowitz+C%22">Moskowitz C</searchLink>; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.<br /><searchLink fieldCode="AU" term="%22Seshan+V%22">Seshan V</searchLink>; Department of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Dogan+A%22">Dogan A</searchLink>; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Salles+G%22">Salles G</searchLink>; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Younes+A%22">Younes A</searchLink>; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Zelenetz+AD%22">Zelenetz AD</searchLink>; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Batlevi+CL%22">Batlevi CL</searchLink>; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007422%22">Leukemia & lymphoma</searchLink> [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 738-741. <i>Date of Electronic Publication: </i>2023 Jan 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9007422 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1029-2403 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210268022%22">10268022 </searchLink><i>NLM ISO Abbreviation: </i>Leuk Lymphoma <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36642966
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2022.2164194
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 738
    Titles:
      – TitleFull: Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Qualls D
      – PersonEntity:
          Name:
            NameFull: Noy A
      – PersonEntity:
          Name:
            NameFull: Straus D
      – PersonEntity:
          Name:
            NameFull: Matasar M
      – PersonEntity:
          Name:
            NameFull: Moskowitz C
      – PersonEntity:
          Name:
            NameFull: Seshan V
      – PersonEntity:
          Name:
            NameFull: Dogan A
      – PersonEntity:
          Name:
            NameFull: Salles G
      – PersonEntity:
          Name:
            NameFull: Younes A
      – PersonEntity:
          Name:
            NameFull: Zelenetz AD
      – PersonEntity:
          Name:
            NameFull: Batlevi CL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2023 Mar
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1029-2403
          Numbering:
            – Type: volume
              Value: 64
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Leukemia & lymphoma
              Type: main
ResultId 1